This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996; 335:865–875.
Kim HL, Belldegrun AS, Freitas DG, Bui MHT, Han KR, Dorey FJ, Figlin RA. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003; 170:1742–1746.
Revill SI, Robinson JO, Rosen M, Gogg MI. The reliability of a linear analogue for evaluation of pain. Anaesthesia 1976; 31:1191–1198.
Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313:84.
Cline MA, Ochoa J, Torebjork HE. Chronic hyperalgesia and skin warming caused by sensitized C nociceptors. Brain 1989; 112:621.
McNicol E, Strassels S, Goudas L, et al. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol 2004; 22:1975.
Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43:273.
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41(3):273–281.
Simmonds MA. Management of breakthrough pain due to cancer. Oncology 1999; 13(8):1103–1108; discussion 1110, 1113–1114.
Hegarty A, Portnoy RK. Pharmacotherapy of neuropathic pain. Sem Neurol 1994; 14:213–224.
Portenoy RK. Adjuvant analgesics. In: Cherny NI, Foley JM, Eds. Hematology/Oncology Clinics of North America: Pain And Palliative Care, Vol 10. Philadelphia: Saunders, 1996, p. 103.
Wooldridge JE, Anderson CM, Perry MC. Corticosteroids in advanced cancer. Oncology 2001; 15:225–234.
Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD. Current use of bisphosphonates in oncology. J Clin Oncol 1998; 16(12):3890–3899.
Stasi R, Abiani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue. Cancer 2003; 98:1786–1801.
Weert v E, Hoekstra-Weebers J, Otter R, Postema K, Sanderman R, Schans van der C. Cancer-related fatigue: predictors and effect of rehabilitation. The Oncologist 2006; 11:184–196.
Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990; 112(7):499–504.
Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29:12.
Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology. 1995; 105(1):31–57.
Jones TH, Wadler S, Hupart KH. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 1998; 25(1 Suppl 1):54–63.
Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001; 24(4):287–293.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag London Limited
About this chapter
Cite this chapter
Richel, D. (2008). Palliative Treatment in Renal Cell Cancer. In: Rosette, J.J.d., Sternberg, C.N., Poppel, H.P.v. (eds) Renal Cell Cancer. Springer, London. https://doi.org/10.1007/978-1-84628-763-3_58
Download citation
DOI: https://doi.org/10.1007/978-1-84628-763-3_58
Publisher Name: Springer, London
Print ISBN: 978-1-84628-385-7
Online ISBN: 978-1-84628-763-3
eBook Packages: MedicineMedicine (R0)